Skip to main content

Nivolumab

Question for Department of Health

UIN 22970, tabled on 18 January 2016

To ask the Secretary of State for Health, what information his Department holds on the effects of nivolumab on one year survival rates for lung cancer.

Answered on

29 January 2016

Nivolumab is currently marketed in the European Union under the brand name Opdivo.


The data available when Opdivo was licensed in 2015 indicated overall survival among patients given the product was around nine months, whereas among the patients given docetaxel, another cancer medicine, it was six months.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.